Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00108485
Recruitment Status : Terminated (Unable to recruit sufficient study subjects)
First Posted : April 18, 2005
Results First Posted : May 12, 2016
Last Update Posted : June 22, 2016
Information provided by (Responsible Party):
Ronald Goldberg, University of Miami

Brief Summary:
The primary purpose of this study is to test the effectiveness and tolerability of Niaspan® to improve the levels of blood fats ("good" and "bad" cholesterol and triglyceride levels) in people who have kidney damage due to diabetes. A secondary goal is to test whether Niaspan® slows down further development of kidney damage.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Kidney Failure, Chronic Hyperlipidemia Drug: Extended release niacin Other: Placebo Phase 3

Detailed Description:
Diabetic nephropathy is the leading cause of end stage kidney disease in the United States. Patients with chronic kidney disease have a markedly increased risk of death from cardiovascular disease, and traditional risk factors such as hyperlipidemia have been shown to be of critical importance. Almost 90% of patients with diabetes and chronic kidney disease have lipid abnormalities. Here, we investigate whether Niaspan, taken in addition to lipid-lowering drugs referred to as "statins", will decrease LDL cholesterol and increase LDL particle size, increase HDL, reduce proteinuria, and reduce the speed of loss of renal function.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment
Study Start Date : April 2005
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Arm Intervention/treatment
Active Comparator: Extended release niacin
Extended release niacin 1500-2000 mg daily versus placebo comparator
Drug: Extended release niacin
Extended release niacin 1500-2000mg once daily
Other Name: Niaspan

Placebo Comparator: Placebo
Placebo tablets
Other: Placebo
Placebo tablets

Primary Outcome Measures :
  1. Change in Proteinuria [ Time Frame: Baseline, 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of type 2 diabetes
  • Diagnosis of chronic kidney disease stage 2 or 3 with an estimated GFR of 30-89 ml/min using the four variable MDRD (Modification of Diet in Renal Disease Study Group) formula
  • Presence of microalbuminuria or proteinuria less than 3.5 g/d
  • Diagnosis of hyperlipidemia currently treated with a "statin" drug

Exclusion Criteria:

  • Not meeting inclusion criteria
  • HDL-C > 40 mg/dL for men, > 50 mg/dL for women
  • TG (triglycerides) < 150 mg/dL and > 800 mg/dL
  • Documented intolerance to Niaspan or Aspirin
  • Treatment with other lipid-lowering agents (fibrates, BAS [bile acid sequestrants], or ezetimibe)
  • Elevated transaminases (AST or ALT >1.3 x ULN)
  • Unstable type 2 diabetes (FBG >200 mg/dL or HbA1c >9.5%)
  • Known seropositivity for Hepatitis B, C, or HIV
  • Documented history of malignancy
  • Age < 18 years
  • Pregnant women or nursing mothers
  • Inability to give informed consent
  • Start or change in "statin" dose < 2 months ago

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00108485

Layout table for location information
United States, Florida
Univesity of Miami/Diabetes Research Institute
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
Layout table for investigator information
Principal Investigator: Ronald Goldberg, MD University of Miami, Miami, FL
Layout table for additonal information
Responsible Party: Ronald Goldberg, Professor of Medicine, University of Miami Identifier: NCT00108485    
Other Study ID Numbers: 20043224
First Posted: April 18, 2005    Key Record Dates
Results First Posted: May 12, 2016
Last Update Posted: June 22, 2016
Last Verified: May 2016
Keywords provided by Ronald Goldberg, University of Miami:
Diabetes Mellitus, Type 2
Kidney Failure, Chronic
Randomized Controlled Trials
Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Diabetic Nephropathies
Kidney Failure, Chronic
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Kidney Diseases
Urologic Diseases
Lipid Metabolism Disorders
Diabetes Complications
Renal Insufficiency, Chronic
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Vasodilator Agents
Vitamin B Complex
Physiological Effects of Drugs